[HTML] nature.comFull View

[HTML][HTML] Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

CKH Wong, JJ Lau, ICH Au, KTK Lau, IFN Hung… - Nature …, 2023 - nature.com
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …
被引用次数：4 相关文章
[PDF] d24h.hk

[PDF][PDF] Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or 2 diagnosis: a target trial emulation 3

CKH Wong, JJ Lau, ICH Au, KTK Lau, I FN - d24h.hk
Page 1 of 39 Title Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom
onset or diagnosis: a target trial Page 1 Page 1 of 39 Title 1 Optimal timing of nirmatrelvir/ritonavir …
[HTML] nih.gov

[HTML][HTML] Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

CKH Wong, JJ Lau, ICH Au, KTK Lau… - Nature …, 2023 - ncbi.nlm.nih.gov
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

CKH Wong, JJ Lau, ICH Au, KTK Lau… - Nature …, 2023 - ideas.repec.org
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

CKH Wong, JJ Lau, ICH Au, KTK Lau… - Nature …, 2023 - ui.adsabs.harvard.edu
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation.

CKH Wong, JJ Lau, ICH Au, KTK Lau… - Nature …, 2023 - search.ebscohost.com
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

C Wong, J Lau, I Au, K Lau, I Hung, M Peiris… - Nature …, 2023 - europepmc.org
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

CKH Wong, JJ Lau, ICH Au, KTK Lau… - Nature …, 2023 - econpapers.repec.org
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

CKH Wong, JJ Lau, ICH Au, KTK Lau… - Nature …, 2023 - pubmed.ncbi.nlm.nih.gov
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …

Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation.

CKH Wong, JJ Lau, ICH Au, KTK Lau… - Nature …, 2023 - europepmc.org
Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …